ArticlePloS one2014
Prion protein-specific antibodies that detect multiple TSE agents with high sensitivity.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Acute LPS exposure enhances susceptibility to peripheral prion infection.Scientific reports · 2025Article
- Bovine spongiform encephalopathy: A review of current knowledge and challenges.Open veterinary journal · 2025Review
- Cell adhesion molecule CD44 is dispensable for reactive astrocyte activation during prion disease.Scientific reports · 2024Article
- Microglia deficiency accelerates prion disease but does not enhance prion accumulation in the brain.Glia · 2022Article
- Innate Immune Tolerance in Microglia Does Not Impact on Central Nervous System Prion Disease.Frontiers in cellular neuroscience · 2022Article
- Caprine PRNP polymorphisms N146S and Q222K are associated with proteolytic cleavage of PrPGenetics, selection, evolution : GSE · 2021Article
- Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection.PLoS pathogens · 2021Article
- Spermine increases acetylation of tubulins and facilitates autophagic degradation of prion aggregates.Scientific reports · 2018Article
- Prion disease pathogenesis in the absence of the commensal microbiota.The Journal of general virology · 2017Article
- Distribution of Misfolded Prion Protein Seeding Activity Alone Does Not Predict Regions of Neurodegeneration.PLoS biology · 2016Article
- PrP aggregation can be seeded by pre-formed recombinant PrP amyloid fibrils without the replication of infectious prions.Acta neuropathologica · 2016Article
- The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species.Journal of virology · 2015Article
- Prion protein-specific antibodies-development, modes of action and therapeutics application.Viruses · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
This paper describes the generation, characterisation and potential applications of a panel of novel anti-prion protein monoclonal antibodies (mAbs). The mAbs were generated by immunising PRNP null mice, using a variety of regimes, with a truncated form of recombinant ovine prion protein spanning residues 94-233. Epitopes of specific antibodies were mapped using solid-phase Pepscan analysis and clustered to four distinct regions within the PrP molecule. We have demonstrated the utility of these antibodies by use of Western blotting and immunohistochemistry in tissues from a range of different species affected by transmissible spongiform encephalopathy (TSE). In comparative tests against extensively-used and widely-published, commercially available antibodies, similar or improved results can be obtained using these new mAbs, specifically in terms of sensitivity of detection. Since many of these antibodies recognise native PrPC, they could also be applied to a broad range of immunoassays such as flow cytometry, DELFIA analysis or immunoprecipitation. We are using these reagents to increase our understanding of TSE pathogenesis and for use in potential diagnostic screening assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.